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PERSONAL VIEW
Vaccinate boys as well as girls against HPV: it works,
and it may be cost effective
Protecting boys as well as girls by vaccinating against human papillomavirus may cut the incidence
of genital warts and several cancers among both sexes, writes Gillian Prue
Gillian Prue lecturer in chronic illness, School of Nursing and Midwifery, Queen’s University Belfast,
Belfast BT9 7BL
Human papillomavirus (HPV) infection is common in men.
Many of these infections are transient and clinically
insignificant, but persistent infection with HPV types 6 and 11
can lead to genital warts, and oncogenic types 16 and 18 may
lead to some head and neck, anal, or penile cancers. The
incidence of each of these cancers has increased worldwide in
the past two decades, and HPV causes 5% of all human cancers.
Since September 2008 a free vaccination programme has been
available for 12-13 year old girls in the United Kingdom, with
a catch-up programme to vaccinate girls aged up to 18. Australia,
the United States, two Canadian provinces, and Austria have
introduced vaccination for boys as well as girls. And now the
UK’s Joint Committee on Vaccination and Immunisation, an
advisory committee of the Department of Health, is investigating
whether to extend the HPV vaccination programme to boys (see
www.gov.uk/government/groups/joint-committee-on-
vaccination-and-immunisation). The cost effectiveness of the
vaccine is a key consideration.
HPV related disease in men causes a considerable burden;
therefore, vaccinating boys is likely to produce more health and
economic benefits than those from a girls-only programme. A
study of 4065 males aged 16-26 found that the quadrivalent
HPV vaccine prevented genital warts and penile and anal
cancer.1And ameta-analysis of 22 studies (including 8360men)
examining men’s attitudes and acceptance regarding HPV
vaccination found a moderate level of acceptance in this
population.2
Various mathematical models have estimated the potential
impact of a male vaccination programme, and its cost
effectiveness is debated. Many models do not support the
inclusion of men, but specifically men who have sex with men
(MSM) are often excluded, and the focus is largely on the effect
of the vaccine in terms of cervical cancer outcomes and not on
predicting its effect on other cancers related to HPV.3 A recent
Norwegian study considered all HPV related diseases and
extending the programme to boys. It concluded that, although
it might be cost effective to include boys, increasing the
coverage in girls was uniformly more effective and cost
effective.4
If uptake is low in girls, the benefit of vaccinating boys is easily
apparent. However, with high uptake in girls, vaccinating both
sexes is less cost effective. Nevertheless, a European study that
assessedmale vaccination and all HPV carcinomas showed that
vaccinating 12 year old boys and girls would be associated with
substantial additional clinical benefits—namely, reduced
incidence of HPV related genital warts and carcinomas,
compared with vaccinating only girls.3 This additional benefit
was noted even with an overall coverage of only 70%. In
addition, a two dose schedule (in place of the current three dose
schedule) will be introduced in the UK in September5; this will
increase the cost effectiveness of a vaccinating boys as well as
girls.
Although the UK’s vaccination programme reaches more than
80% of girls, many communities have much lower coverage
rates: in half of London’s primary care trust areas less than 80%
of girls are vaccinated6; and a University College London study
found that uptake was lower among minority ethnic groups.7
Concerns are also growing that some new “academy” schools
may not accommodate school nurses and vaccination
programmes.8Uptake may also be low for boys in these groups,
but vaccinating them would help to protect the girls. Boys
themselves would be protected from acquiring HPV infection
from non-vaccinated women and from other men.
The current girls-only vaccination programme leaves MSM at
particular risk of infection because they do not benefit from any
herd protection. Indeed, a programme targeted at MSM in the
UK may be the most effective; its benefit may be limited,
however, because many MSM acquire HPV as teenagers9 and
may have been exposed to HPV already.
As for men who have sex with women, the extent to which they
benefit from a girls-only vaccination programme even with a
high uptake may also be limited. For example, in Denmark HPV
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vaccination has significantly reduced the incidence of genital
warts among women but not among men.10
The suffering caused by HPV related diseases is self evident.
The economic costs are also considerable: a study of treating
nine major HPV related diseases in Italy produced an estimate
of almost €530m (£420m; $714m) a year.11 And the cost of
treating genital warts was almost £17m in England in 2008.12
Ultimately, any decision about whether to vaccinate boys should
not be based solely on cost effectiveness. Public health, equity,
and the human costs of HPV related disease for both sexes must
be the main considerations.
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